CHina Adrenal Venous saMPling InvestigatiON
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese Academy of Medical Sciences, Fuwai Hospital
About this trial
Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.
Eligibility criteria
Qualifiers
Patients with confirmed primary aldosteronism;
Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.
Disqualifiers
Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；
An estimated glomerular filtration rate <45 ml/min/1.73 m2, or serum creatinine >176 μmol/L；
Patients who refuse adrenalectomy;
Suspected of having an adrenocortical carcinoma;
Trial design
Treatments tested in this trial
- adrenal venous sampling
Treatment groups
5,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov